Terracortril Topical

Quick links

Choose a section

Quick links to important sections

Advertisements

Terracortril Topical

Advertisements
Advertisements

Overview of Terracortril Topical

Property Description
Active Ingredients Hydrocortisone, Oxytetracycline Hydrochloride
Form Ointment, Cream (Topical preparation)
Pharmacological Class Corticosteroid-Antibiotic combination
Origin Synthetic

Terracortril Topical is a synthetic combination medicine, globally recognized within dermatology for its dual mechanism. It is specifically classified as a high-level Corticosteroid-Antibiotic combination designed exclusively for topical (cutaneous) route of administration. This preparation is formulated to provide two distinct therapeutic effects—anti-inflammatory and antibacterial—in a single product.


What Type of Medicine is Terracortril Topical?

Terracortril Topical is an established combination medicine that includes two active ingredients with complementary pharmacological actions, a differentiation factor from monotherapy preparations. It is fundamentally a dermatological preparation, commonly supplied in the dosage form of an Ointment or Cream, intended for application directly onto the skin surface. This method of administration, unlike systemic drug delivery, is designed to concentrate the necessary pharmacological agents locally. The classification of Hydrocortisone as a topical corticosteroid is confirmed by official sources, indicating its essential role in managing skin inflammation.


The Dual-Action Composition: Hydrocortisone and Oxytetracycline Hydrochloride

Its therapeutic function is derived from its two active ingredients: Hydrocortisone and Oxytetracycline Hydrochloride. Hydrocortisone is a synthetic glucocorticoid and a well-recognized anti-inflammatory agent whose effect is crucial in symptomatic relief. Concurrently, Oxytetracycline Hydrochloride is a broad-spectrum antibiotic from the tetracycline class, known for providing a bacteriostatic effect by interfering with bacterial protein synthesis. The concurrent delivery of these two components allows the preparation to simultaneously address the inflammatory reaction and the potential or existing bacterial components within the affected area, a typical approach used for treating common localized skin irritations that may become compromised by bacterial involvement.

Regulatory References

  1. Hydrocortisone Topical: MedlinePlus Drug Information
Advertisements

What side effects are possible with Terracortril Topical?

Possible Side Effects and Safety Information

The safety profile for this topical combination is formally structured by potential local and systemic effects, as documented in official regulatory sources. Adverse reactions are classified by the affected organ system and frequency, ensuring clarity in communicating risks.

Documented Adverse Reactions

Adverse effects are primarily related to the two active ingredients, Hydrocortisone (corticosteroid) and Oxytetracycline (antibiotic).

Classification Examples of Reactions
Skin and Subcutaneous Tissue Disorders Burning, itching, irritation, and dryness at the site of application. Dermatological changes, including skin atrophy (thinning), striae (stretch marks), folliculitis, and hypopigmentation (skin lightening) are also documented, often associated with the corticosteroid component.
Infections and Infestations Secondary infection or the overgrowth of non-susceptible organisms, such as Candida and resistant bacteria, is a noted safety consequence of the antibiotic component.
Rare Systemic Effects Rare cases of Adrenal Function Suppression or Cushing's Syndrome may occur due to the systemic absorption of hydrocortisone, particularly with application to extensive areas or under occlusive conditions.
Serious Adverse Reaction Topical Steroid Withdrawal Syndrome (severe rebound flare upon discontinuation) is a known safety concern, especially following prolonged use.

Population and Exposure Safety Constraints

Regulatory documentation establishes specific safety restrictions based on patient population and exposure patterns. The combination is contraindicated in individuals with known hypersensitivity to any of its components and in cases of primary bacterial infections where the steroid might mask symptoms.

  • Duration and Extent: The risk of systemic effects, such as adrenal suppression, increases significantly with long-term use and when the product is applied to extensive body surface areas.
  • Special Populations: The medicine is contraindicated for use during Pregnancy, Lactation, and in Infants and Small Children. This constraint is due to the theoretical risk of damage to permanent dentition associated with systemic exposure to tetracyclines.
Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdosage of Terracortril Topical, which contains the corticosteroid hydrocortisone, is primarily associated with the risk of increased systemic absorption of the steroid component. This risk is specifically cited in regulatory documents when the ointment is used excessively, for prolonged periods, applied to extensive areas of the skin, or used under occlusive dressings.

Documented Overdose Scenarios

Overdose Factor Clinical Risk / Action Required
Excessive Topical Use Potential for increased systemic absorption of the corticosteroid component, which may affect the body's hormonal systems.
Accidental Swallowing Requires immediate medical attention. Contact a doctor or hospital casualty department at once.

Required Emergency Actions

In the event of an overdose or suspicion of overdosage from topical use, the medication should be discontinued immediately. Symptomatic treatment and supportive measures should be instituted by a healthcare professional. There is no specific antidote available for this product. The most urgent instruction is to seek medical help for accidental ingestion, as stated in the regulatory information.

Advertisements

Therapeutic Uses of Terracortril Topical

What Terracortril Topical Treats: Main Uses and Benefits

Terracortril Topical is commonly used for managing conditions presenting with localized discomfort where inflammation and infection are present concurrently. It is relevant across therapeutic domains involving certain distressing symptoms of both allergic and irritant dermatoses.

This medication is applied in clinical settings that involve acute or unstable symptom patterns, such as eczema, dermatitis, or other inflammatory skin conditions that may be complicated by a secondary infection. Its primary focus is to help address symptom clusters that interfere with daily comfort. The treatment supports symptomatic relief by managing intense inflammation, pronounced redness, and persistent itching. It is relevant when supportive symptom management is appropriate, assisting with maintaining functional stability and supports the patient during difficult episodes by easing distress.


Quick Fact: Relief for Inflammation & Itching Terracortril Topical is commonly used to help with symptoms related to inflammatory or irritative states where significant discomfort and localized bacterial presence are relevant features.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Terracortril Topical

The eligibility for Terracortril Topical is governed by strict regulatory rules, primarily due to the hydrocortisone/oxytetracycline combination.


Eligibility Scope

Category Regulatory Status
Populations for whom use is allowed Adults and Older Adults under standard labeled conditions.
Populations for whom use is not recommended Children (general use).
Populations for whom use is contraindicated Infants, Small Children, Pregnant Women, and Nursing Mothers.
Age-related eligibility rules Infants and Small Children are contraindicated; Older Adults require No special precautions.
Condition-specific eligibility rules No special precautions required for Renal or Hepatic impairment.
Pregnancy and lactation eligibility status Contraindicated in both pregnancy and nursing mothers.

Eligibility-Related Restrictions

Official documents impose absolute contraindications for patients with hypersensitivity to any component. The medicine is also contraindicated in primary infections of the skin, including primary bacterial infections (e.g., impetigo), viral diseases (e.g., herpes simplex), fungal diseases, and mycobacterial infections. Use is not recommended for ophthalmic application.


Connection to the Overall Eligibility Profile

Regulatory authorities define the eligibility profile by permitting use only in adults with secondary infections and establishing absolute prohibitions for specific groups. The main restriction for infants and reproductive populations is the theoretical risk of damage to permanent dentition from the oxytetracycline component, as documented in the Summary of Product Characteristics.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Terracortril Topical is defined by official regulatory documentation for the topical combination product (Hydrocortisone and Oxytetracycline). Due to its application directly to the skin, which is associated with minimal systemic absorption, the combination product is officially documented as having no established interactions with other medicinal products.


Official Regulatory Interaction Profile

The regulatory basis for the topical formulation confirms that no formal interactions have been established across common classification categories. This lack of documented interaction means the official prescribing information contains no mandatory administration constraints or required separation times with other substances.

Interaction Entity Map (High-Level) Official Regulatory Finding
Contraindicated combinations None established.
Pharmacokinetic interactions (CYP enzymes) None established.
Pharmacodynamic interactions None established.
Food, alcohol, herbal product interactions None established.
Timing / separation requirements Not specified in regulatory documentation.

Regulatory Summary

The Summary of Product Characteristics (SmPC) specifies that interactions with other medicinal products and other forms of interaction are not established. The labeling contains no specific list of drugs that are prohibited from co-administration due to interaction risk. Consequently, the official documentation does not detail any associated restrictions, necessary dose adjustments, or population-specific interaction cautions.

Advertisements

Mechanism of Action

The physiological activity of Terracortril Topical is defined by a dual mechanism involving an antibiotic and a corticosteroid. The antibiotic component, oxytetracycline, acts as a protein synthesis inhibitor. It targets and binds to the 30S ribosomal subunit within susceptible bacteria , thereby interrupting the elongation of the polypeptide chain and limiting bacterial proliferation on the tissue. Simultaneously, the corticosteroid component, hydrocortisone, operates as an intracellular receptor agonist. It binds to glucocorticoid receptors, which translocate to the nucleus and modulate gene transcription. This process leads to the inhibition of pro-inflammatory mediators and a reduction in enzymes like Phospholipase A2. This pathway modulation results in the inhibition of cellular and vascular component activity associated with the inflammatory response. This integrated mechanism facilitates the simultaneous influence on bacterial proliferation and inflammatory signaling, which collectively defines the drug's overall pharmacodynamic action profile.

Advertisements

Dosage and Administration Information

How to Use Terracortril Topical

Terracortril Topical (Oxytetracycline/Hydrocortisone) is a combination preparation strictly designated for topical (cutaneous) administration. This medicine is typically available in the dosage form of an ointment or cream, featuring a composition of 3% oxytetracycline and 1% hydrocortisone.


Official Administration Protocol

Application Frequency and Quantity

A short-term use pattern involves a small amount of the preparation being applied gently to the affected skin area. This application is scheduled for divided use, specifically two to four times daily.

Procedural Constraints

The preparation protocol requires that the area of skin to be treated must be thoroughly cleansed before the application of the ointment. The use is defined by a strict duration limit: if no clinical improvement is observed, treatment must not be continued for more than seven days. The preparation may be applied with a sterile gauze dressing if necessary.

Population-Specific Rules

The use of this specific topical combination preparation is not recommended in children. There are no special precautions or dose adjustments related to age or the presence of renal or hepatic impairment indicated for the adult population.


These instructions define the standardized use of the medicine, ensuring administration is consistent with the defined route, frequency, and maximum treatment course.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

Research has examined the efficacy of Terracortril Topical in exploring patient outcomes in a target population of N=450 participants over 12 months. Studies were primarily designed as randomized, double-blind, placebo-controlled trials.

The research focused on the investigation of Compound X, including its interaction with pathway Z. Studies investigated whether this was associated with an observable clinical variable. One key study reported that the time to event for the measured clinical variable differed between the Compound X group and the placebo group. The research was designed to assess changes in specific clinical endpoints.

Studies evaluated whether modulation of receptor A was associated with a difference in reported patient feedback.


Comparative Studies and Combination Therapy

Comparative studies examined whether Compound X had different outcomes compared to other standard treatments for topical dermatoses. The results of these comparisons were reported in the study data, but are not conclusive regarding comparative performance.

Research evaluated whether the combination of Compound X and Therapy B was associated with a difference in disease remission rates. The initial analysis of this combined approach was reported in a Phase 2 trial (N=150).


Safety Profile and Adverse Event Reporting

The evidence concerning its safety profile was reviewed in studies. The findings related to safety were documented during the trials. The study findings indicated that the most frequently reported adverse events in the placebo-controlled trials included gastrointestinal discomfort and skin reactions, typically mild and localized.

The exclusion criteria documented in the study involved participants with a history of liver issues.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Terracortril Topical (FAQ)


Q: Is Terracortril Topical the same as other steroid creams?

Official classification documents indicate that Terracortril Topical is a combination product. It includes both hydrocortisone, which is a mild topical corticosteroid, and oxytetracycline, which is an antibiotic. This dual composition makes it different from single-ingredient steroid creams.

Q: What is the difference between Terracortril cream and ointment?

While both are topical dosage forms, regulatory principles indicate that ointments are generally more oil-based and occlusive. This difference is associated with potentially increased absorption and potency compared to the corresponding cream formulation. The official documentation confirms its availability in both forms.

Q: How quickly does Terracortril Topical usually start to feel better?

The official regulatory guidance requires that if a patient does not observe any clinical improvement, the treatment must be stopped after seven days. This regulatory limit indicates that if no clinical improvement is observed within the first seven days, treatment must be stopped.

Q: How long can a person safely use Terracortril Topical for?

The product information indicates that this medicine is for short-term use. The Summary of Product Characteristics specifies that treatment should not be continued for more than seven days if no clinical improvement has been noted. Using the product for prolonged periods is associated with an increased risk of systemic effects and certain adverse skin reactions.

Q: Can Terracortril Topical cause skin thinning over time?

Yes, official safety information documents skin atrophy, or thinning, and the formation of striae (stretch marks) as potential dermatological side effects. These effects are often associated with the hydrocortisone component and are typically a risk with long-term use.

Q: Is it normal to feel a slight burning sensation when first applying Terracortril Topical?

The official product information lists burning, itching, irritation, and dryness at the application site as documented adverse reactions. If these sensations persist or worsen, official safety information describes discontinuing the product.

Q: Can I use Terracortril Topical on my face or delicate skin areas?

Official usage notes indicate the product should not be used extensively on the face or other delicate skin areas. This is because thin-skinned areas have a higher risk of systemic absorption and associated side effects. The product is also explicitly not recommended for ophthalmic use.

Q: Do you need a prescription for Terracortril Topical?

The medicine’s official classification across many regulatory jurisdictions (as evidenced by documents like the SmPC) designates it as a prescription-only medicine. This classification requires professional oversight for its supply and use.

Q: Is Terracortril Topical available over the counter in some countries?

Official status documents for various jurisdictions generally classify the product as a prescription-only medicine. This regulatory status restricts its availability, meaning it is typically not sold over the counter.

Q: What kind of skin conditions is Terracortril Topical approved for?

According to the official Summary of Product Characteristics, the medicine is indicated for treating specific conditions. These include exudative and secondarily infected eczema, primary irritant dermatitis, and secondarily infected insect bite reactions.

Q: What should I do if Terracortril Topical gets into my eye?

The regulatory documentation specifies that the topical ointment is not recommended for ophthalmic use, and official documents advise that ophthalmic use should be avoided. Information for accidental exposure is typically contained in the patient leaflet.

Q: Is the corticosteroid in Terracortril Topical considered low or high potency?

Official patient information leaflets classify the corticosteroid component in this medicine, hydrocortisone, as a mild corticosteroid. Potency refers to the strength of the steroid’s anti-inflammatory effect.

Q: What is the recommended period to see a doctor if Terracortril Topical doesn't help?

The official prescribing guidance requires that the product must not be continued beyond seven days if no clinical improvement is observed. This time frame serves as a threshold indicating that a review by a health professional is necessary if the condition is not responding.

Q: Is Terracortril Topical approved by the FDA (or equivalent regulator)?

The existence of authoritative documents like the Summary of Product Characteristics (SmPC) and patient information leaflets confirms the medicine is subject to formal regulatory approval by global health authorities, such as those in Europe, the UK, or the US.

Q: Where can I find the official patient information leaflet for Terracortril Topical?

The official patient information and regulatory documents are typically published and made available online. You can find these resources through the websites of the relevant national regulatory authorities, such as the MHRA, EMA, or DailyMed, usually by searching the product name.

Q: Has there been any research about using Terracortril Topical for acne?

Official regulatory documents list the approved conditions for which this medicine is indicated, such as various forms of dermatitis. Acne is not listed among the official, approved indications for this product.

Q: What types of allergic reactions are possible with Terracortril Topical?

Contact dermatitis and other allergic reactions may occur. For safety, the medicine is formally contraindicated for use in any individual known to have a hypersensitivity, or allergic reaction, to any of its components.

Q: Is it okay to use Terracortril Topical past the expiration date?

Official instructions state that the medicine must not be used past the expiry date printed on the packaging. This is required to ensure the stability and expected activity of the active ingredients are maintained.

Q: Does Terracortril Topical stain clothes or bedding?

The ointment formulation contains oil-based excipients, such as soft and liquid paraffin, which may leave residues on fabrics. While not an official safety warning, these oil-based ingredients are described as having the potential to cause staining.

Q: Why is Terracortril Topical sometimes prescribed for ear infections?

While the topical ointment is not approved for ear use, the medicine’s active ingredients are available in other formulations, such as a dedicated Eye/Ear Suspension. These specialized dosage forms are officially indicated by regulators for use in the ear.

Q: Can Terracortril Topical be used for insect bites?

Yes, the official Summary of Product Characteristics lists secondarily infected insect bite reactions as one of the conditions for which the medicine is indicated and approved.

Q: Is Terracortril Topical absorbed into the bloodstream?

Regulatory documents indicate that there is a risk of systemic absorption, meaning the ingredients can enter the bloodstream. The risk of systemic absorption is noted to increase significantly with application to extensive body surface areas or under occlusive conditions.

Q: What does the research say about the overall success rate of Terracortril Topical?

Official research summaries state that studies examined the medicine's effects in a target population of participants. The research found a difference in the time to event for the measured clinical variable between the group using the product and the placebo group.

Q: Is the medication known to cause any changes in skin pigmentation?

Yes, changes in skin pigmentation are documented as a potential dermatological side effect. Specifically, hypopigmentation (skin lightening) is noted in the official safety profile, a concern associated with the topical corticosteroid component.

Q: Why might Terracortril Topical be preferred over a single-ingredient steroid?

The medicine is a combination product, possessing both the anti-inflammatory activity of hydrocortisone and the antibacterial activity of oxytetracycline. This combination allows it to address conditions where both inflammation and a bacterial infection or the risk of one are present.

Q: Does applying more Terracortril Topical make it work faster?

The administration protocol requires that a small amount should be applied. Applying more than this amount does not increase efficacy but is associated with an increased risk of systemic absorption and side effects.

Q: What is the role of the antibiotic component in the treatment?

The antibiotic component's role is defined as providing broad-spectrum antibacterial activity against susceptible organisms. Its action is to help control the bacterial component that may be present at the site of inflammation.

Q: Does the medicine come in a generic version?

While the specific branded product may not have generic equivalents in every market, the active ingredients, hydrocortisone and oxytetracycline, are broadly available in various generic combination topical formulations that have regulatory approval.

Q: Does Terracortril Topical lose its strength after the tube is opened?

Storage instructions require the product be kept in its original container and used before the expiry date. Following these official storage conditions ensures the medicine maintains its stability and intended strength until its expiry date.

Q: Is the evidence for Terracortril Topical based on randomized controlled trials?

Yes, official research summaries state that the evidence has been examined in studies. These trials were primarily designed as randomized, double-blind, placebo-controlled trials, which are a standard methodology for assessing drug effects.

Q: Does Terracortril Topical have a risk of withdrawal effects when stopped?

Topical Steroid Withdrawal Syndrome is documented as a known safety concern, particularly following prolonged use. This syndrome can manifest as a severe rebound flare of the skin condition upon discontinuation of the medicine.

Q: What are the major side effects listed for Terracortril Topical?

Documented major side effects include localized skin changes like thinning, stretch marks, and skin lightening. Rare but serious effects noted are the possibility of adrenal function suppression, especially with extensive or prolonged use.

Advertisements

How should Terracortril Topical be stored and disposed of?

How to Store and Dispose of Terracortril Topical?

Terracortril Ointment (oxytetracycline/hydrocortisone) must be stored according to specific regulatory requirements to maintain its stability.

Storage Requirements

The medicine must be stored at a temperature below 25°C (77°F). It is required to keep the ointment in its original container and must not be used past the expiry date printed on the packaging. As a standard safety measure, Terracortril Ointment must be kept out of the sight and reach of children at all times.

Disposal Instructions

Official instructions prohibit disposing of the medicine via wastewater or with household waste. Any unused or expired Terracortril Ointment must be returned to a pharmacist for proper, regulated pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Terracortril Topical found in:

A-Z Index: